UPCOMING EVENTS
NEWS
MSN: What is Shelf-Stable Synthetic Bood? The Scientific Advancement That Could Transform Battlefield and Emergency Care
This article highlights a recent report and lab visit by Military Times, spotlighting a breakthrough effort funded by Defense Advanced Research Projects Agency (DARPA) and developed by biotech firm KaloCyte in collaboration with researchers at the University of Maryland, Baltimore.
Defense News Weekly: DARPA Develops Synthetic Blood for the Battlefield (Part 1)
Military Times recently interviewed KaloCyte co-founder Allan Doctor as featured in Part One of this two-part video series on DARPA’s development of synthetic blood.
Defense, Science & Technology News: DARPA Develops Powdered Blood Substitute for Battlefield Use
DARPA, the Pentagon’s research agency, is making strides in battlefield medicine with the development of a powdered blood substitute, seeking partnerships to advance testing. The program director expressed optimism about the potential of this innovative product, particularly in the context of modern military operations where traditional blood supply may face challenges.
Epsiloon, Le Magazine Scientifique d’Actualite: Artificial Blood: Finally!
KaloCyte’s work on ErythroMer is featured in this French article on artificial blood substitutes currently in development.
Happiest Health: Lab Grown Liquid Life
KaloCyte Co-Founders Dr. Allan Doctor and Dr. Dipanjan Pan are among several experts featured in this article on blood substitute research, showcasing KaloCyte’s development of ErythroMer.
Biosynthetic Blood Breakthrough: Chrysea and KaloCyte Enter into Exclusive Alliance to Transform Medical Emergency Care
Chrysea and KaloCyte have entered into an exclusive license agreement, forging a global partnership that combines Chrysea’s synthetic biology expertise in production of biosynthetic hemoglobin with KaloCyte’s innovative artificial red blood cell technology.
ZDFhuete: ZDF Morning Magazine: Moma Future: Blood in Powder Form
KaloCyte’s Chief Scientific Officer, Dr. Allan Doctor, was interviewed on German television for this feature showcasing development of ErythroMer. (in German, subtitles unavailable).
Pushkin Podcasts: What’s Your Problem? Reinventing Blood
Dr. Allan Doctor, co-founder and chief scientific officer at KaloCyte, speaks with host Jacob Goldstein explaining the complex science behind artificial blood, and how this innovation could help save millions of lives.
CBS News – WJZ Baltimore: Synthetic, Shelf-stable Blood Developed by Maryland Scientist Could Save Lives in Emergencies
Scientists at the University of Maryland School of Medicine believe the technology could prove invaluable for paramedics, the military, and even future space missions where access to traditional blood transfusions is not possible.
NPR, Shots – Health News: Scientists are Developing Artificial Blood that Could Save Lives in Emergencies
NPR health correspondent Rob Stein expands on his recent visit with Dr. Allan Doctor at UMB, including photos featuring KaloCyte team members at work in the KaloCyte lab.

CONTACT US
KaloCyte, Inc.
4 N. Martin Luther King Jr. Blvd
Suite 300
Baltimore, MD 21201
QUICK LINKS
ABOUT US
KaloCyte was founded by a distinguished team of researchers in physiology, bioengineering, and trauma care and is poised to deliver ErythroMer, a dried, bio-inspired artificial red blood cell, to market. ErythroMer is envisioned for use when stored red blood cells are unavailable, undesirable or in short supply. KaloCyte is supported by over $20M in federal grants and investor funding.




